RE:RE:What is the next step?I really hope they were able to get US analysts and investors to their R&D day. If we get the same people as we do every 3 months, I wont count on them to get to excited and suddently promote the potential. And by looking at the Trading today and since thursday we can guess that they did not get any attention from US people so far. Why they would be waiting the R&D day to hear what they should have read so far ? I guess we will need a lot more than that. We need a good momentum of good news . lets do what we had done so far: lets hope and wait .... AGAIN :o)
SPCEO1 wrote: The first thing we should hope to see in the couple of weeks after the R&D Day is US analysts picking up coverage of the stock with the theme of their report being that you can buy TH stock and get the potential of HIV NASH for free. I would expect these analysts to note the uncertainty surrounding the unique circumstances of Dr. Grinspoon's trial, which was not an sanctioned phase II FDA trial. But they should also note the data he came up with was indeed promising and that it is likely the FDA will allow TH to go forward with at least a phase IIb/III trial than could gain approval if the results confirms everyone's suspicions. They also might hold out some hope for label expansion in HIV NAFLD. Since the shelf offering is in place, the analysts may be more than willing to take up TH's cause as they would hope to gain their firm some nice feesin any share offering.
The next milestone after the analysts intial reports would be the results of the meeting with the FDA, which will likely come in February (although the actual meeting would be in January). If the outcome fo that meeting is positive, the analysts will note that Egrifta in HIV NASH has been significantly de-risked and take their targets for the stock higher.
TH would then likely follow that development up quite quickly with a share offering. The stock will likely hit an intermidiate peak just prior to that offering.
That is my best guess for how things develop from here but there are surely going to be other things to consider along the way. But the R&D Day is a key event and management (actually more Dr. Grinspoon) needs to step up and do a great job in order to get the ball rolling.
Bucknelly21 wrote: After r&d day what would be the things we should look for following that. I'm curious anyone's thoughts on this, I'm guessing we don't hear about a trial before eoy and my guess is institutional investors would want to find out that outcome before they spend